Akebia Therapeutics Inc (NASDAQ:AKBA)
| 0.5634 Delayed Data As of Mar 30 |  -0.0418 / -6.91%Today’s Change | 0.24 Today|||52-Week Range 2.34 | -2.36% Year-to-Date |
Latest AKBA News | Press Releases
No recent news for Akebia Therapeutics Inc.
Today’s Trading
| Previous close | 0.61 |
| Today’s open | 0.60 |
| Day’s range | 0.55 - 0.61 |
| Volume | 1,194,704 |
| Average volume (3 months) | 2,159,966 |
| Market cap | $115.6M |
Data as of 3:59pm ET, 03/30/2023
Growth & Valuation
| Earnings growth (last year) | +70.29% |
| Earnings growth (this year) | +2.61% |
| Earnings growth (next 5 years) | +15.80% |
| Revenue growth (last year) | +37.00% |
| P/E ratio | NM |
| Price/Sales | 0.36 |
| Price/Book | 12.37 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SLGLSol Gel Technologies... | -0.17 | -4.05% |
| ---- | ||
| MNOVMediciNova Inc | -0.02 | -0.92% |
| DRRXDURECT Corp | 0.00 | 0.00% |
Data as of 3:59pm ET, 03/30/2023
Financials
| Next reporting date | May 8, 2023 |
| EPS forecast (this quarter) | -$0.15 |
| Annual revenue (last year) | $292.6M |
| Annual profit (last year) | -$92.6M |
| Net profit margin | -31.63% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
